NRAS and acute myeloid leukemia: A more recent NGS analysis of 71 patients with NPM1-mutated AML yielded the following results: DNMT3A (62%), FLT3-ITD (38%), FLT3-TKD (14%), TET2 (27%), IDH2 (23%), IDH1 (18%), PTPN11 (18%) and NRAS (17%) [77].